Search

Keywords: hydrochlorothiazide; photo-induced purpura; solar capillaritis; solar purpura EN hydrochlorothiazide photo-induced purpura solar capillaritis solar purpura 82 84 3 01/17/23 20230101 NES 230101 Solar capillaritis (also referred to as solar purpura) is a rare phenomenon consisting in the appearance of acute purpuric lesions related to solar exposure. Hydrochlorothiazide, photo-induced purpura, solar capillaritis, solar purpura 1988; 5 (1): 47 - 48. 4 Kalivas J, Kalivas L. Solar purpura appearing in a patient with polymorphous light eruption. [Extracted from the article]

Dear Editor, Cutaneous manifestations of coronavirus disease 2019 (COVID-19), including pseudo-chilblain, vesicular, maculopapular, urticaria, and livedo/necrosis1 lesions, have been widely reported. Other patients with COVID-19 and thrombotic events develop antiphospholipid antibodies, suggesting an antiphospholipid syndrome-like condition.5 Cemiplimab is a novel anti-PD-1 therapy recently approved for locally advanced or metastatic cutaneous SCC. [Extracted from the article]

The article describes the case of a 21-year-old white, Spanish man with primary cutaneous anaplastic large cell lymphoma simulating an aggressive angiocentric T-cell lymphoma. The man has a three week history of asymptomatic nodules on his arms. Results of his histopathological examination showed diffuse dermal and subcutaneous infiltrate composed of large and pleomorphic cells. He was treated with low-dose methotrexate.

Background and Objectives Methods Results Conclusions Survival analyses can provide valuable insights into effectiveness and safety as perceived by prescribers. Here, we aimed to evaluate adalimumab (ADA) survival and the interruption risk factors in a multicentre cohort of patients with hidradenitis suppurativa (HS). Moreover, we performed a subanalysis considering the periods before and after the onset of the COVID‐19 pandemic.We conducted a retrospective study including 539 adult patients with HS who received ADA from 1 May 2015 to 31 December 2022. Overall drug survival was analysed using Kaplan–Meier survival curves and compared between the subgroups via stratified log‐rank test. Possible predictors for overall drug survival and reasons for discontinuation were assessed using univariate and multivariate Cox regression.Overall, 50.1% were females with a mean age of 43.5 ± 1 years and a mean BMI of 29.5 ± 6.7. At the start of ADA, 95.29% were biologic‐naïve and 24.63% had undergone surgical treatment. During follow‐up, 9.46% of patients required dose escalation, while 39.92% interrupted ADA. Concomitant therapy was used in 64.89% of cases. A subanalyses comparing pre‐ and post‐pandemic periods revealed a tendency to initiate ADA treatment at a younger age, among patient with higher BMI and at a lower HS stage after COVID‐19 pandemic. Interestingly, ADA demonstrated extended survival compared to previous studies, with a median overall drug survival of 56.2 months (95% CI 51.2 to 80.3). The primary causes for discontinuation were inefficacy (51.69%), followed by adverse effects (21.35%). Female sex, longer delay in HS diagnosis, higher baseline IHS4 score and concomitant spondyloarthritis were associated with poorer ADA survival or increased risk of discontinuation.ADA demonstrated prolonged survival (median 56.2 months). While addition of antibiotics did not have a positive effect on survival rate, basal IHS4 proved useful in predicting ADA survival. [ABSTRACT FROM AUTHOR]

Bullous pemphigoid is an acquired autoimmune blistering disorder affecting mostly elderly people that is rare in children. There have been fewer than 100 cases of childhood bullous pemphigoid reported. Childhood bullous pemphigoid ( CBP) generally has a good prognosis. Remission is usually achieved within several weeks to a few months, and relapses are rare, although refractory cases can occur, and the disease may be life threatening, particularly when lesions generalize. Herein we describe the case of an infant with severe CBP refractory to multiple treatments. In our case, therapy with azathioprine and intravenous immunoglobulin resulted in a slight clinical response, but only combined with high doses of prednisolone. Administration of rituximab led to a complete clinical response and allowed almost complete steroid tapering. There are no current guidelines indicating what doses and frequency of rituximab are safest or most effective in children with blistering diseases. [ABSTRACT FROM AUTHOR]